Reviva Pharmaceuticals Holdings, Inc. Current Income Tax Expense (Benefit)
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Current Income Tax Expense (Benefit) of $18.89 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-30
- Reviva Pharmaceuticals Holdings, Inc. current income tax expense (benefit) for fiscal 2025 was $18.89K, a 3.20% decline from fiscal 2024.
- Reviva Pharmaceuticals Holdings, Inc. current income tax expense (benefit) for fiscal 2024 was $19.51K, a 15.13% increase from fiscal 2023.
- Reviva Pharmaceuticals Holdings, Inc. current income tax expense (benefit) for fiscal 2023 was $16.95K, a 18.42% decline from fiscal 2022.
- Reviva Pharmaceuticals Holdings, Inc. current income tax expense (benefit) for fiscal 2022 was $20.78K, a 159.71% increase from fiscal 2021.
| Period end | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $18.89K 10-K · filed 2026-03-30 | |
| 2024-12-31 | $19.51K 10-K · filed 2026-03-30 | |
| 2023-12-31 | $16.95K 10-K · filed 2025-04-03 | |
| 2022-12-31 | $20.78K 10-K · filed 2024-04-15 | $21.00K 10-K · filed 2023-03-30 |
| 2021-12-31 | $8.00K 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |